| Full Name | Ellen Rees |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 2 East Rd, Alford, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295782878 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 152468 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ellen Rees, MD Po Box 420, Great Barrington, MA 01230-0420 Ph: (413) 528-4561 | Ellen Rees, MD 2 East Rd, Alford, MA 01230-1946 Ph: (413) 528-4561 |
News Archive
A nutritional supplement could stimulate the production of stem cells integral for repairing the body. Research published in BioMed Central's open access Journal of Translational Medicine suggests that a commercially-available supplement can increase the blood circulation of hematopoietic stem cells, which can give rise to all blood cells, and endothelial progenitor cells, which repair damage to blood vessels.
Transcranial direct-current stimulation -a non-invasive technique for applying electric current to areas of the brain-may be growing in popularity, but new research suggests that it probably does not add any meaningful benefit to cognitive training.
Massachusetts' two largest insurers have again asked regulators for permission to increase their rates. "Blue Cross Blue Shield of Massachusetts, the state's biggest health insurer, is requesting increases averaging 12 percent, on the lower end of the range it submitted earlier in the spring. Harvard Pilgrim Health Care, the number two carrier, wants increases that range from 8.8 percent to 11.9 percent, about the same range it sought in the round that was rejected" (Weisman, 6/3).
Paclitaxel is a powerful anticancer agent used to treat a variety of malignancies, but severe side effects limit its ultimate effectiveness and utility. To improve this drug's pharmacological properties, researchers have turned to nanoparticle-based delivery agents, although with marginal success; stably trapping large amounts of paclitaxel in most nanoparticles has proven difficult.
New data presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrate that in cancer patients with CDI, DIFICLIR(fidaxomicin) may offer significant benefits in terms of clinical cure, recurrence and sustained clinical cure.
› Verified 5 days ago
Jack A Miller, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 384 West Rd, Alford, MA 01266 Phone: 413-644-9755 |